MiMedx Group Inc (MDXG)

MiMedx Group Inc. is a healthcare company listed on the NASDAQ under the ticker MDXG. The company develops and distributes placental tissue allografts used in wound care, burn care, and surgical applications. Its products are made from human placental membrane, umbilical cord, and placental disc tissues processed through its proprietary PURION method, which is designed to preserve key biological components while using aseptic processing and terminal sterilization techniques.

MiMedx’s portfolio includes wound care products such as EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets, as well as surgical and other offerings including AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT. These products are used in areas such as lower extremity repair, plastic surgery, vascular surgery, and orthopedic repair and reconstruction. The company sells through a direct sales force and independent sales agents, and also works with individual customers and independent distributors in the United States. MiMedx was founded in 2006 and is headquartered in Marietta, Georgia.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-MDXG
$5.22
6.0% Upside
Fair
$7.40
50.1% Upside
Bargain
Great
0.0%
November 4, 2026
115.2x
3.3x
2.0x
718.6 M
600 M
2.4%
78.7%
8.4
713.3%
Valuation • Fair Value

MiMedx Group Inc (NASDAQ-MDXG) Fair Value by Valuation Model

Review the available estimates for MiMedx Group Inc (NASDAQ-MDXG), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.22

Estimated upside of 6.0% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$5.92

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0.47

Classic Ben Graham valuation formula reference.

EPV Fair Value

$5.28

Earnings power value estimate.

Comps Fair Value

$4.52

Comparable-company valuation reference.

Analyst Price Target

$7.40

Analysts imply upside of 50.1%.

How to read these valuation models

Use the 7 available valuation references for MiMedx Group Inc (NASDAQ-MDXG) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for MiMedx Group Inc (NASDAQ-MDXG)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

355.2 M

Current operating scale indicator.

Revenue Forecast

271 M

Forward revenue estimate.

EBITDA

20.411 M

Current operating profitability reference.

EBITDA Forecast

-3.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review MiMedx Group Inc (NASDAQ-MDXG) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for MiMedx Group Inc (NASDAQ-MDXG)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-3.41

No elevated caution signal from this screen.

Altman Z-Score

8.4

Relatively strong balance-sheet zone.

FCF / Net Income

713.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for MiMedx Group Inc (NASDAQ-MDXG). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for MiMedx Group Inc (NASDAQ-MDXG)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 4, 2026

Days to Earnings

43

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for MiMedx Group Inc (NASDAQ-MDXG), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

MiMedx Group Inc (NASDAQ-MDXG) Stock Forecast & Technical Outlook

Review MiMedx Group Inc (NASDAQ-MDXG) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for MiMedx Group Inc (NASDAQ-MDXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for MiMedx Group Inc (NASDAQ-MDXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for MiMedx Group Inc (NASDAQ-MDXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for MiMedx Group Inc (NASDAQ-MDXG) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for MiMedx Group Inc (NASDAQ-MDXG) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for MiMedx Group Inc (NASDAQ-MDXG)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, MiMedx Group Inc (NASDAQ-MDXG) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ Fast Investor Answers

MiMedx Group Inc (NASDAQ-MDXG) Stock FAQ

Data-supported answers about MiMedx Group Inc (NASDAQ-MDXG), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.22
Estimated upside 6.0%
Valuation Rating
Undervalued
Estimated upside of 6.0%
Analyst Target
$7.40
Implied upside 50.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for MiMedx Group Inc (NASDAQ-MDXG) is $5.22. This implies an estimated upside of 6.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.0% versus the current market price.

The available analyst price target for MiMedx Group Inc (NASDAQ-MDXG) is $7.40. The analyst target implies estimated upside of 50.1%.

The current financial health read for MiMedx Group Inc (NASDAQ-MDXG) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for MiMedx Group Inc (NASDAQ-MDXG) is November 4, 2026.

The latest available data indicates no current dividend yield for MiMedx Group Inc (NASDAQ-MDXG).

The current P/E ratio listed for MiMedx Group Inc (NASDAQ-MDXG) is 115.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for MiMedx Group Inc is 718.6 M.

The current enterprise value listed for MiMedx Group Inc is 600 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for MiMedx Group Inc is NASDAQ-MDXG, and the stock is listed on NASDAQ.

MiMedx Group Inc (NASDAQ-MDXG) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for MiMedx Group Inc is 2.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for MiMedx Group Inc is 78.7%. Free float helps investors understand how much of the share base is available for public trading.